Freshness note: This analysis was last updated 25 days ago. Fast-moving policy claims can change quickly, so check for newer official updates before relying on this verdict.

Mixed Evidencehealth

90% of health care spending treats chronic disease

Published February 20, 2026Updated February 20, 2026

Summary

The claim that 90% of healthcare spending treats chronic disease is an overstatement of the actual figures. Federal health agencies report that chronic diseases account for approximately 75-90% of healthcare spending, with the most commonly cited figure from the Centers for Disease Control and Prevention being 90% of the nation's $4.5 trillion in annual healthcare expenditures, though this appears to include broadly defined chronic conditions and may represent an upper-bound estimate.

Primary Sources

CDC states that chronic diseases are responsible for 7 of 10 deaths and account for 90% of the nation's $4.5 trillion in annual healthcare expenditures

Official national health expenditure data and projections from the Centers for Medicare & Medicaid Services

CDC program describing chronic disease burden and prevention efforts

Research studies have estimated chronic disease spending at varying percentages depending on methodology and disease definitions used

Economic analysis of chronic disease burden on the US healthcare system

Evidence Supporting the Claim

  • The CDC states on its chronic disease overview page that chronic diseases account for 90% of the nation's $4.5 trillion in annual healthcare expenditures
  • The CDC reports that six in ten Americans live with at least one chronic disease, and four in ten have two or more
  • Multiple federal health agencies acknowledge that chronic diseases represent the largest driver of healthcare costs in the United States
  • The 90% figure has been cited in official CDC communications and public health materials

Evidence Against / Context

  • The 90% figure represents an upper-bound estimate and varies depending on how chronic diseases are defined and categorized
  • Other estimates from health policy research organizations place chronic disease spending between 75-86% of total healthcare expenditures
  • The CDC figure includes a broad range of conditions under the chronic disease category, including mental health conditions and some conditions that may be debated as chronic
  • Different methodologies for calculating disease-attributable spending produce different percentages, and direct treatment costs may differ from total economic burden
  • The specific breakdown of what constitutes treatment for chronic disease versus preventive care, acute complications, or end-of-life care can affect the calculation

Timeline

  • CDC began prominently citing the 90% figure in chronic disease overview materials

  • National health expenditure reached approximately $4.5 trillion according to CMS data

  • Robert F. Kennedy Jr. and administration officials cited the 90% statistic in public communications

  • The statistic appeared on RealFood.gov and in statements about healthcare policy priorities

What This Means

Structured interpretation — not opinion

  • Key takeaway 1

    The 90% figure comes from official CDC sources and represents a defensible upper-bound estimate of chronic disease healthcare spending, making the claim technically supportable

  • Key takeaway 2

    The statistic depends significantly on how chronic diseases are defined, what conditions are included, and how spending is attributed to specific diseases versus general healthcare

  • Key takeaway 3

    The broad consensus among health policy experts is that chronic diseases account for the majority of US healthcare spending, though the exact percentage varies by methodology

  • Key takeaway 4

    The claim lacks important context about how this percentage is calculated and what categories of spending and disease definitions are included

Related Claims in health

Mixed Evidence

The FDA was changing leucovorin's label because it could help 'hundreds of thousands' of children with autism

FDA Commissioner Marty Makary announced in September 2025 that the agency would change leucovorin's label to reflect potential benefits for some children with autism and cerebral folate deficiency. However, the FDA later clarified the label change applied to a rare subset of patients with a specific metabolic condition, not hundreds of thousands of children, and the agency disputed characterizations that overstated the scope of the change.

Supported by Evidence

The Trump administration enacted a 6-month moratorium on Minnesota Medicaid payments

On February 27, 2026, the Trump administration implemented a six-month moratorium on federal Medicaid payments to Minnesota through the Centers for Medicare and Medicaid Services. The action was taken in response to Minnesota's policies regarding undocumented immigrants' access to state healthcare programs, which federal officials characterized as violations of federal law.

Not Supported by Evidence

Americans are now paying the lowest price anywhere in the world for drugs, thanks to the administration's negotiations with pharmaceutical companies

The claim that Americans pay the lowest drug prices in the world is contradicted by international data. While the Trump administration negotiated some drug pricing agreements, U.S. prescription drug prices remain substantially higher than those in other developed countries.

Privacy & Cookie Choices

We use cookies for analytics and advertising. By clicking “Accept” you consent to the use of cookies. See our Privacy Policy for details.